Qiagen N.V. (QGEN) Receives $32.56 Consensus Target Price from Analysts
Shares of Qiagen N.V. (NASDAQ:QGEN) have received an average recommendation of “Hold” from the fifteen research firms that are currently covering the firm, MarketBeat reports. Nine analysts have rated the stock with a hold rating and five have issued a buy rating on the company. The average 12 month target price among brokers that have covered the stock in the last year is $32.56.
Several equities research analysts have commented on QGEN shares. TheStreet lowered shares of Qiagen N.V. from a “b-” rating to a “c” rating in a research report on Monday, April 24th. Deutsche Bank AG restated a “buy” rating on shares of Qiagen N.V. in a research report on Tuesday, May 2nd. Commerzbank Ag restated a “buy” rating on shares of Qiagen N.V. in a research report on Friday, June 23rd. Barclays PLC restated a “buy” rating and set a $33.00 target price on shares of Qiagen N.V. in a research report on Monday, May 15th. Finally, Morgan Stanley restated an “overweight” rating and set a $37.00 target price (up from $36.00) on shares of Qiagen N.V. in a research report on Monday, July 10th.
Qiagen N.V. (NASDAQ QGEN) traded up 0.96% during mid-day trading on Friday, reaching $31.55. The company’s stock had a trading volume of 932,546 shares. The company has a 50 day moving average of $32.99 and a 200-day moving average of $31.27. Qiagen N.V. has a 52-week low of $24.86 and a 52-week high of $35.26. The stock has a market cap of $7.20 billion, a PE ratio of 96.48 and a beta of 1.14.
Qiagen N.V. (NASDAQ:QGEN) last issued its earnings results on Thursday, July 27th. The company reported $0.30 EPS for the quarter, topping the consensus estimate of $0.28 by $0.02. The company had revenue of $349 million for the quarter, compared to analyst estimates of $353.09 million. Qiagen N.V. had a net margin of 5.44% and a return on equity of 11.04%. The business’s revenue was up 4.4% on a year-over-year basis. During the same period in the previous year, the firm earned $0.24 EPS. Equities analysts forecast that Qiagen N.V. will post $1.22 earnings per share for the current year.
Large investors have recently added to or reduced their stakes in the company. Acrospire Investment Management LLC raised its stake in Qiagen N.V. by 11.7% in the second quarter. Acrospire Investment Management LLC now owns 3,344 shares of the company’s stock valued at $112,000 after buying an additional 349 shares in the last quarter. FNY Managed Accounts LLC acquired a new stake in Qiagen N.V. during the first quarter valued at approximately $103,000. Oppenheimer Asset Management Inc. acquired a new stake in Qiagen N.V. during the first quarter valued at approximately $114,000. Quadrant Capital Group LLC raised its stake in Qiagen N.V. by 4.1% in the second quarter. Quadrant Capital Group LLC now owns 5,742 shares of the company’s stock valued at $183,000 after buying an additional 225 shares in the last quarter. Finally, Quantitative Systematic Strategies LLC acquired a new stake in Qiagen N.V. during the second quarter valued at approximately $211,000. Institutional investors and hedge funds own 60.07% of the company’s stock.
Qiagen N.V. Company Profile
QIAGEN N.V. (QIAGEN) is a holding company. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials.
Receive News & Ratings for Qiagen N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen N.V. and related companies with Analyst Ratings Network's FREE daily email newsletter.